-+ 0.00%
-+ 0.00%
-+ 0.00%

ImmunityBio Receives FDA Expanded Access Authorization For Treatment Of Lymphopenia With ANKTIVA In Patients With Solid Tumors

Benzinga·06/02/2025 13:04:54
Listen to the news
  • Authorized expanded access for ANKTIVA to treat lymphopenia, a life-threatening immune deficiency induced by chemotherapy, radiotherapy, and immunotherapy with depletion of natural killer (NK) and CD4+ CD8+ T cells (lymphocytes)
  • Expanded Access includes all patients with solid tumors who have failed first-line treatment on chemotherapy, radiotherapy or immunotherapy and exhibit low Absolute Lymphocyte Counts (ALC <1,000/μL)
    • Presentation at ASCO Annual Meeting 2025 of lymphopenia treatment in patients with 3rd to 6th line metastatic pancreatic cancer significantly prolongs overall survival